https://www.selleckchem.com/products/atuzabrutinib.html Trail running is characterised by large elevation gains/losses and uneven varying running surfaces. Limited information is available on injury and illness among trail runners to help guide injury and illness prevention strategies. The primary aim of this review was to describe the epidemiology of injury and illness among trail runners. Eight electronic databases were systematically searched (MEDLINE Ovid, PubMed, Scopus, SportsDiscus, CINAHL, Health Source Nursing/Academic, Health Source Consumer Ed., and Cochrane) from inception to November 2020. The search was conducted according to the PRISMA statement and the study was registered on PROSPERO international prospective register of systematic reviews (CRD42019135933). Full-text English and French studies that investigated injury and/or illness among trail runners participating in training/racing were included. The main outcome measurements included trail running injury (incidence, prevalence, anatomical site, tissue type, pathology-type/specific diagnoific areas for future research were identified that could improve the management of trail running injury and illness. In patients with chronic obstructive pulmonary disease (COPD), small airway dysfunction (SAD) is a key element and a functional consequence of the pathology. The exact role of SAD as a specific 'pharmacological target' represents an important research topic. Our objective was to ascertain whether an extra-fine formulation of beclomethasone dipropionate/formoterol fumarate (BDP/FF) NEXThaler 100/6μg b.i.d. could improve SAD and, consequently, the quality of life of COPD patients. We enrolled COPD patients with severe airflow obstruction and at least one moderate exacerbation in the previous year, having started treatment with BDP/FF NEXThaler for no more than 1 week. Patients underwent three visits at the start of the treatment (V1), 6 weeks (V2), and 12weeks later (V3). At each visit, we evaluated